Bristol Myers Squibb ZENBEXUS Wins FDA Accelerated Approval for Multiple Myeloma
The FDA has granted accelerated approval to Bristol Myers Squibb ZENBEXUS (iberdomide), the first CELMoD therapy ever cleared, paired with daratumumab and dexamethasone for multiple myeloma patients as early as first relapse.
